Name
Purdue University Globle
NU580 FNP II – Primary Care of Children and Adolescents’ Health
Prof. Name
Date
Hyperthyroidism in children is uncommon but can affect growth, development, cardiovascular health, bone maturation, and daily functioning if it remains untreated. Graves disease is the most common cause of pediatric hyperthyroidism, and diagnosis generally involves thyroid function tests and evaluation for thyroid antibodies. Methimazole is the preferred first-line antithyroid medication for most children, while persistent or medication-resistant disease may require radioactive iodine or thyroidectomy. Because treatment requires careful dosing and monitoring, children with confirmed hyperthyroidism should receive care from a pediatric endocrinologist.
Hyperthyroidism occurs when the thyroid gland produces excessive amounts of thyroid hormones, primarily thyroxine (T4) and triiodothyronine (T3). These hormones influence metabolism, heart rate, temperature regulation, growth, and the function of multiple organ systems.
Pediatric hyperthyroidism is considerably less common than hypothyroidism. Graves disease, an autoimmune disorder caused by antibodies that stimulate the thyroid gland, accounts for most cases in children and adolescents.
Other possible causes include:
Autonomously functioning thyroid nodules
Familial nonautoimmune hyperthyroidism
McCune-Albright syndrome
Thyroiditis
Exogenous or factitious thyroid hormone exposure
Rare genetic or thyroid hormone disorders
Untreated hyperthyroidism can interfere with normal growth and puberty and may contribute to cardiovascular, skeletal, cognitive, and behavioral complications.
The symptoms of hyperthyroidism reflect an increased metabolic state and may develop gradually. In children, some manifestations can be mistaken for behavioral changes, anxiety, or problems at school.
Common signs and symptoms include:
Weight loss despite a normal or increased appetite
Rapid heartbeat or persistent tachycardia
Heat intolerance
Excessive sweating
Tremors, particularly fine hand tremors
Irritability or anxiety
Hyperactivity
Difficulty sleeping
Fatigue or reduced exercise tolerance
Difficulty concentrating
Declining academic performance
Goiter or thyroid enlargement
Changes in growth or puberty
Children with Graves disease may also develop eye findings, such as eye irritation or prominence, although the severity of thyroid eye disease varies.
A careful history and physical examination are important because symptoms alone cannot establish the diagnosis.
Diagnosis combines clinical findings with laboratory testing. The initial evaluation generally focuses on determining whether thyroid hormone production is excessive and identifying the underlying cause.
Common laboratory tests include:
Thyroid-stimulating hormone (TSH)
Free T4
Total or free T3
Thyroid antibodies, particularly antibodies associated with Graves disease
In primary hyperthyroidism, TSH is typically suppressed while circulating thyroid hormone levels are elevated. T3 testing can be particularly useful because some patients may have T3-predominant hyperthyroidism, in which T3 is elevated while free T4 is not yet clearly elevated.
Thyroid receptor antibodies, including thyroid-stimulating immunoglobulin (TSI) or TSH receptor antibodies (TRAb), can support the diagnosis of Graves disease.
Imaging is not necessarily required for every child. When the diagnosis or cause remains uncertain, additional evaluation may include thyroid ultrasound or thyroid scintigraphy.
Thyroid ultrasound can help evaluate thyroid enlargement, nodules, and other structural abnormalities. Doppler ultrasound may also provide information about thyroid blood flow.
Thyroid scintigraphy or radioactive iodine uptake testing can help distinguish different causes of thyrotoxicosis, particularly when antibody testing is inconclusive or an autonomously functioning thyroid nodule is suspected.
The choice of testing depends on the child’s clinical presentation, laboratory findings, age, and suspected cause.
Treatment is individualized according to the underlying cause, severity of disease, age, response to therapy, and potential adverse effects. The main goals are to normalize thyroid hormone levels, control symptoms, prevent complications, and achieve long-term remission when possible.
Methimazole is generally the preferred antithyroid medication for children with Graves disease. It reduces thyroid hormone synthesis and is typically used as the initial medical treatment.
Methimazole is preferred over propylthiouracil (PTU) because PTU carries a risk of serious liver injury. Pediatric treatment guidelines therefore generally recommend avoiding PTU except in specific circumstances.
Treatment requires periodic thyroid function testing so that medication doses can be adjusted as thyroid hormone levels change.
Propylthiouracil can cause serious hepatotoxicity, including potentially life-threatening liver failure. Because methimazole is generally available as a safer alternative for children, PTU is not routinely used for pediatric Graves disease.
Special clinical circumstances may occasionally lead a specialist to consider PTU, but this is not the usual first-line approach.
Families should receive clear instructions about possible adverse effects before treatment begins. Some reactions are uncommon but potentially serious.
Parents or caregivers should promptly contact the child’s healthcare provider if the child develops:
Fever
Sore throat
Unusual weakness
Yellowing of the skin or eyes
Dark urine
Severe abdominal pain
Significant rash
Symptoms of an allergic reaction
Fever and sore throat can be warning signs of agranulocytosis, a rare but serious reduction in neutrophils. Liver-related symptoms can indicate hepatic injury.
Routine blood counts or liver-function testing are not necessarily required for every asymptomatic child; testing is generally guided by symptoms and clinical circumstances. The treating clinician should provide specific instructions.
Children with suspected or confirmed hyperthyroidism should be evaluated by a pediatric endocrinologist. Specialist involvement is particularly important because treatment requires careful interpretation of thyroid laboratory results, medication adjustment, and monitoring of growth and development.
A pediatric endocrinologist may help with:
Confirming the diagnosis
Determining the underlying cause
Selecting and adjusting antithyroid medication
Monitoring thyroid hormone levels
Managing adverse effects
Assessing growth and pubertal development
Evaluating remission or relapse
Considering definitive treatment when appropriate
Some children continue to have hyperthyroidism despite medical therapy, experience significant medication-related problems, or have circumstances that make definitive treatment appropriate.
The principal definitive treatment options are:
Radioactive iodine (RAI) therapy
Thyroidectomy
The choice depends on factors such as the child’s age, thyroid size, disease severity, treatment response, family preferences, and the expertise of the treating team.
Radioactive iodine destroys thyroid tissue and can provide definitive treatment for Graves disease. It is used selectively in children and requires careful consideration of age, disease characteristics, and radiation-related factors.
Thyroidectomy may be considered when a child has a large goiter, suspicious thyroid nodules, significant medication intolerance, or other clinical circumstances that make surgery appropriate.
Because definitive treatment can result in hypothyroidism, children who develop inadequate thyroid hormone production generally require lifelong levothyroxine replacement therapy.
Pediatric hyperthyroidism requires ongoing follow-up because thyroid hormone levels can change during treatment, and Graves disease can relapse.
Follow-up typically includes monitoring:
TSH, free T4, and T3 as clinically indicated
Medication effectiveness and adverse effects
Heart rate and other clinical symptoms
Growth and weight
Pubertal development
Bone health when clinically indicated
Signs of remission or relapse
During the early treatment period, thyroid function is usually reassessed frequently, with the exact interval determined by the child’s clinical status and treatment regimen. Once thyroid hormone levels stabilize, follow-up intervals can generally be extended.
Long-term management is important because remission does not occur in every child treated for Graves disease, and relapse can occur after a period of control.
Controlling excess thyroid hormone helps reduce the effects of prolonged metabolic stimulation. Effective treatment can improve symptoms such as tachycardia, heat intolerance, tremors, sleep difficulties, and fatigue.
Appropriate management also supports:
Normal growth and development
Healthy weight maintenance
Bone development
Cardiovascular health
Concentration and school functioning
Physical activity and daily functioning
Early recognition and consistent follow-up are particularly important during childhood and adolescence because these are critical periods for physical and neurological development.
Primary care clinicians may be among the first healthcare professionals to recognize pediatric hyperthyroidism. Persistent tachycardia, weight loss, heat intolerance, tremors, behavioral changes, goiter, or unexplained changes in school performance should prompt consideration of thyroid disease when clinically appropriate.
Important clinical points include:
Graves disease is the most common cause of hyperthyroidism in children.
Diagnosis generally requires thyroid function testing and evaluation of the underlying cause.
TSH, free T4, and T3 are important components of the laboratory evaluation.
Thyroid antibodies can help identify Graves disease.
Methimazole is generally the preferred first-line antithyroid medication for children.
PTU is generally avoided because of its risk of severe liver toxicity.
Children with confirmed hyperthyroidism should receive pediatric endocrinology care.
Medication safety education is essential for families.
Persistent or recurrent disease may require radioactive iodine or thyroidectomy.
Long-term follow-up is necessary to monitor treatment response, remission, relapse, growth, and development.
Pediatric hyperthyroidism is an important endocrine condition for healthcare professionals to recognize because untreated thyroid hormone excess can affect multiple aspects of a child’s health. For a NU580 Unit 5 discussion, key considerations include recognizing Graves disease as the leading cause, understanding the role of TSH and thyroid hormone testing, identifying methimazole as the usual first-line medication, and recognizing the importance of pediatric endocrinology referral and long-term monitoring.
Treatment decisions should be individualized based on disease severity, thyroid hormone levels, response to medication, adverse effects, likelihood of remission, and the child’s overall clinical circumstances.
American Thyroid Association. (2022). Hyperthyroidism (overactive thyroid). https://www.thyroid.org/hyperthyroidism/
Garzon Maaks, D. L., Barber Starr, N., Brady, M. A., Gaylord, N. M., Driessnack, M., & Duderstadt, K. G. (2020). Burns’ pediatric primary care (7th ed.). Elsevier.
Hanley, P., Lord, K., & Bauer, A. J. (2016). Thyroid disorders in children and adolescents: A review. JAMA Pediatrics, 170(10), 1008–1019. https://doi.org/10.1001/jamapediatrics.2016.0486
National Institute of Diabetes and Digestive and Kidney Diseases. (2023). Hyperthyroidism (overactive thyroid). https://www.niddk.nih.gov/health-information/endocrine-diseases/hyperthyroidism
Segni, M. (2017). Disorders of the thyroid gland in infancy, childhood, and adolescence. Endotext. National Library of Medicine. https://www.ncbi.nlm.nih.gov/books/NBK279032/
